ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Editas to use CRISPR on natural killer cells

by Ryan Cross
February 22, 2019 | APPEARED IN VOLUME 97, ISSUE 8

 

Gamida Cell and the CRISPR gene-editing company Editas Medicine are joining forces to create a cancer therapy with natural killer (NK) cells. Gamida has a chemical method to expand the growth of NK cells, a kind of immune cell that can target tumors. A Phase I study of Gamida’s NK cell therapy for treating blood cancers is underway. Editas plans to engineer Gamida’s NK cells to make them better at killing tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment